Laurus Labs Limited (LAURUSLABS)

Loading page…

Laurus Labs Limited (LAURUSLABS) · mywealthgrid

About

Laurus Labs operates in pharmaceuticals within the healthcare sector, generating quarterly revenues of ₹1,500–₹2,000 Cr with net profits of ₹175–₹362 Cr. At ₹96.5k Cr market cap, it is a mid-tier Indian pharma company with strong profitability margins averaging 26% operating profit margin.

Founded: 2005
Face value: ₹2

Market cap

₹1,07,176 Cr

P/E

98.0×

P/B

20.2×

Dividend yield

0.1%

ROE

18.2%

ROCE

21.3%

Debt / equity

0.45

OPM

26.1%

EPS (TTM)

₹20.3

Book value

₹98.2

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

PE ratio of 88.3× is very elevated for a pharmaceutical company, leaving minimal valuation margin if earnings growth slows or quarterly results disappoint.

Operating profit margin volatile (22.91% to 31.5% in recent quarters) — verify what drives margin swings and whether they reflect operational inconsistency or external cost pressures.

Stock surged 113% in one year to ₹1,787, creating elevated momentum risk if growth narrative falters or market sentiment shifts.

Generated analysis · source review pending

Growth drivers

Revenue grew to ₹2,026 Cr (Jun 2026) from ₹1,653 Cr (Sep 2025) — verify if volume-driven or reflects pricing power in key markets.

Operating profit margin expanded from 22.91% (Dec 2025) to 31.5% (Jun 2026) — verify if sustainable cost management or product-mix improvement.

Net profit increased from ₹194 Cr (Sep 2025) to ₹362 Cr (Jun 2026) — verify if core business driver or one-time benefits.

Generated analysis · source review pending

2,415 historical price candles were omitted because the exchange source has not been verified.

₹1,984.0+0.3%1Y

Quick read

rule-based

Pros

+Healthy operating margin of 26.1%

Cons

−Low return on equity of 10.2% (3-yr avg)
−Profit declined 2% a year over the last 5 years
−Modest revenue growth of 7.2% a year over the last 5 years
−Expensive at 98× trailing earnings
−Trading at 20.2× book value

Research score

Structured signal from quality, growth, valuation and momentum.

39/100

Business quality: 61
Growth: 57
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY MIDCAP 50 NIFTY MIDCAP 150 NIFTY 200 NIFTY MIDSMALLCAP 400 NIFTY 500

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	1,811	2,069	2,069	2,292	2,832	4,814	4,936	6,041	5,041	5,554	6,813
COGS	1,018	1,064	1,064	1,236	1,413	2,158	2,194	2,774	2,432	2,478	2,695
Gross profit	793	1,005	1,005	1,056	1,418	2,655	2,742	3,266	2,608	3,076	4,117
	344	592	592	700	854	1,105	1,320	1,677	1,837	2,017	2,339
	449	413	413	356	565	1,551	1,422	1,589	772	1,059	1,778
OPM %	24.8%	20%	20%	15.5%	19.9%	32.2%	28.8%	26.3%	15.3%	19.1%	26.1%
Depreciation	86	125	125	164	187	205	251	324	385	430	480
Interest	—	80	80	88	90	68	102	165	183	216	171
	2	29	29	16	6	24	15	6	26	75	55
Profit before tax	169	237	237	120	294	1,301	1,084	1,106	230	488	1,182
Tax	35	70	70	26	38	317	251	312	68	130	292
Tax %	20.7%	29.4%	29.4%	21.7%	13.1%	24.4%	23.2%	28.2%	29.6%	26.6%	24.7%
	134	168	168	94	255	984	832	793	162	358	890
PAT margin %	7.4%	8.1%	8.1%	4.1%	9%	20.4%	16.9%	13.1%	3.2%	6.5%	13.1%
EPS (₹)	21.4	15.8	15.8	8.8	23.9	18.4	15.4	14.7	3	6.7	16.5
EPS adjusted (₹)	3.3	3.2	3.2	—	4.8	18.3	15.4	14.7	3	6.6	16.5
	0%	9.5%	9.5%	17%	10.4%	6.5%	10.4%	13.6%	53.7%	12%	—
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	82	106	106	107	107	107	108	108	108	108
Reserves	639	1,225	1,377	1,663	2,490	3,244	3,930	4,003	4,365	5,192
Minority interest	—	—	—	—	3	8	11	5	130	131
	734	769	900	956	1,453	1,732	1,972	2,507	2,693	2,397
	388	554	634	1,025	1,697	1,877	1,640	1,764	2,040	2,682
Total equity & liabilities	1,843	2,653	3,017	3,750	5,751	6,968	7,660	8,387	9,336	10,511
	751	1,230	1,481	1,683	2,115	2,514	3,275	3,712	3,934	4,138
CWIP	110	143	163	67	362	813	551	423	458	773
Investments	11	3	3	3	3	31	183	302	233	309
	972	1,277	1,369	1,996	3,270	3,610	3,651	3,950	4,710	5,291
Total assets	1,843	2,653	3,017	3,750	5,751	6,968	7,660	8,387	9,336	10,511

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	46.1%	50.1%	55.2%	55.6%	54.1%	51.7%	55.4%	60.4%
EBITDA margin %	15.5%	19.9%	32.2%	28.8%	26.4%	15.4%	19%	26.1%
EBIT margin %	8.4%	13.3%	28%	23.7%	21%	7.8%	11.3%	19%
PAT margin %	4.1%	9%	20.4%	16.9%	13.1%	3.2%	6.5%	13.1%
Working capital
Receivable days	—	102	99	100	95	120	132	115
Inventory days	—	234	266	293	222	277	285	317
Payable days	—	159	199	146	93	158	141	170
NWC days	—	177	166	247	224	240	276	263
Leverage
Current ratio	—	1.07	1.25	1.25	1.42	1.23	1.22	1.33
Debt to EBITDA	—	1.69	0.94	1.22	1.24	3.22	2.55	1.35
Debt to equity	—	0.54	0.56	0.52	0.49	0.61	0.6	0.45
Interest coverage	2.4	4.3	20.1	11.6	7.7	2.3	3.2	7.9
Asset turnover	—	0.76	0.84	0.71	0.79	0.6	0.59	0.65
Return ratios
Return on assets %	—	6.8%	17.1%	11.9%	10.4%	1.9%	3.8%	8.5%
Return on capital employed %	—	18.6%	51.2%	31.3%	26.8%	8%	12.7%	21.3%
Return on equity %	—	14.4%	37.9%	24.8%	19.7%	3.9%	8%	16.8%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	27.2%	27.19%	27.19%	27.18%	27.18%	27.6%	27.62%	27.59%	27.59%	27.49%	27.49%	27.47%
	24.03%	25.39%	25.97%	25.67%	26.08%	25.56%	25.52%	25.7%	26.16%	26.52%	25.82%	28%
	11.01%	11.14%	11.77%	13.56%	13.05%	12.74%	11.77%	11.94%	11.73%	12.43%	13.97%	13.74%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	37.76%	36.28%	35.07%	33.59%	33.69%	34.1%	35.09%	34.77%	34.52%	33.56%	32.72%	30.79%
No. of shareholders	—	—	—	—	—	—	—	—	2,83,678	2,80,756	2,92,281	2,91,653

Promoter holding up 0.27 percentage points since Sep 2023.

33 deals · 19 Sept 2022 – 31 Aug 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
31 Aug 2026	BNP PARIBAS FINANCIAL MARKETS	Bulk	NSE	Sell	62,72,175	₹1,914.28	₹1,200.67 Cr
31 Aug 2026	INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD.	Bulk	NSE	Sell	51,34,361	₹1,914.04	₹982.74 Cr
31 Aug 2026	SOCIETE GENERALE	Bulk	NSE	Sell	28,10,437	₹1,903.84	₹535.06 Cr
31 Aug 2026	BNP PARIBAS FINANCIAL MARKETS	Bulk	NSE	Buy	15,399	₹1,860.35	₹2.86 Cr
31 Aug 2026	INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD.	Bulk	NSE	Buy	1,718	₹1,922.69	₹0.33 Cr
27 Jan 2025	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Buy	36,90,709	₹536.50	₹198.01 Cr
27 Jan 2025	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Sell	36,89,009	₹536.23	₹197.82 Cr
14 Mar 2023	CYBAGE SOFTWARE PRIVATE LIMITED	Block	NSE	Sell	6,35,894	₹305.00	₹19.39 Cr
14 Mar 2023	ARUN VIJAY NATHANI	Block	NSE	Buy	6,35,894	₹305.00	₹19.39 Cr
14 Nov 2022	ISHARES CORE MSCI EMERGING MARKETS ETF	Block	NSE	Buy	5,29,337	₹455.40	₹24.11 Cr

1–10 of 33

1 / 4

Mr. RAVINDRANATH KANCHERLANon-Executive - Independent Director-Chairperson
Mr. CHAVA SATYANARAYANAExecutive Director-CEO
Mr. VENKATA RAVI KUMAR VANTARAMExecutive Director
Mr. VENKATA LAKSHMANA RAO CHUNDURUExecutive Director
Mr. KRISHNA CHAITANYA CHAVAExecutive Director
Mrs. SOUMYA CHAVAExecutive Director
Mrs. ARUNA RAJENDRA BHINGENon-Executive - Independent Director
Mr. KARNAM SEKARNon-Executive - Independent Director
Mr. RAMESH SUBRAHMANIANNon-Executive - Independent Director
G Venkateswar ReddyCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

End of day 30 Sept 2026 · underlying ₹1,980.0 · volume and open interest in contracts

3

Expiry	Close	Chg	% Chg	Settlement	Open interest	Change in OI	Volume	Lot size
27 Oct 2026	₹1,993.3	-18.5	-0.9%	₹1,993.3	22,261	+154	2,914	850
23 Nov 2026	₹2,005.6	-14	-0.7%	₹2,005.6	844	+173	383	850
29 Dec 2026	₹2,010.0	+1.6	+0.1%	₹2,010.0	13	+13	16	850

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

110

across 17 fund houses

Held by these funds

2.33%

of the company's equity

All mutual funds

10.15%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

110 schemes · 17 fund houses

		Shares
Healthcare Opportunities Fund	SBI Mutual Fund	12 L	229.8	3.96%	0.222%	-0
Small Cap Fund	Axis Mutual Fund	11.57 L	221.51	0.7%	0.214%	-4.61 L
Arbitrage FundNEW	SBI Mutual Fund	7.5 L	143.57	0.3%	0.139%	—
Nifty Pharma ETF	Nippon India Mutual Fund	6.76 L	129.53	7.36%	0.125%	+11,543
Multicap Fund	Axis Mutual Fund	5.6 L	107.21	0.89%	0.104%	-0
(LIVE SCHEMES)	ITI Mutual Fund	4.54 L	86.93	2.41%	0.084%	-0
NIFTY MIDCAP 150 MOMENTUM 50 INDEX FUND	Tata Mutual Fund	4.21 L	80.58	6.32%	0.078%	+3,238
Nifty 500 Momentum 50 Index Fund	Nippon India Mutual Fund	3.91 L	74.79	5.64%	0.072%	+5,749

1–8 of 110

1 / 14

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

23 announcementsExport CSV

25 Jul 2026, 11:37 amCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

24 Jul 2026, 10:59 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Analyst / Investor Meet PDF

24 Jul 2026, 2:57 pmCompany Update

Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press Release / Media Release PDF

24 Jul 2026, 2:55 pmCompany Update

Announcement under Regulation 30 (LODR)-Investor Presentation

Investor Presentation PDF

24 Jul 2026, 2:54 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Directorate

Change in Directorate PDF

24 Jul 2026, 2:51 pmBoard Meeting

Board Meeting Outcome for Outcome Of Board Meeting

Outcome of Board Meeting PDF

24 Jul 2026, 2:48 pmResult

Results - Financial Results For Quarter Ended 30.06.2026

Financial Results PDF

14 Jul 2026, 12:12 pmCompany Update

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 PDF

Date	Category	Subject	Filing
25 Jul 2026, 11:37 am	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
24 Jul 2026, 10:59 pm	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	46.1%	50.1%	55.2%	55.6%	54.1%	51.7%	55.4%	60.4%
EBITDA margin %	15.5%	19.9%	32.2%	28.8%	26.4%	15.4%	19%	26.1%
EBIT margin %	8.4%	13.3%	28%	23.7%	21%	7.8%	11.3%	19%
PAT margin %	4.1%	9%	20.4%	16.9%	13.1%	3.2%	6.5%	13.1%
Working capital
Receivable days	—	102	99	100	95	120	132	115
Inventory days	—	234	266	293	222	277	285	317
Payable days	—	159	199	146	93	158	141	170
NWC days	—	177	166	247	224	240	276	263
Leverage
Current ratio	—	1.07	1.25	1.25	1.42	1.23	1.22	1.33
Debt to EBITDA	—	1.69	0.94	1.22	1.24	3.22	2.55	1.35
Debt to equity	—	0.54	0.56	0.52	0.49	0.61	0.6	0.45
Interest coverage	2.4	4.3	20.1	11.6	7.7	2.3	3.2	7.9
Asset turnover	—	0.76	0.84	0.71	0.79	0.6	0.59	0.65
Return ratios
Return on assets %	—	6.8%	17.1%	11.9%	10.4%	1.9%	3.8%	8.5%
Return on capital employed %	—	18.6%	51.2%	31.3%	26.8%	8%	12.7%	21.3%
Return on equity %	—	14.4%	37.9%	24.8%	19.7%	3.9%	8%	16.8%

29

27 Oct 2026 23 Nov 2026 29 Dec 2026

Calls				Strike	Puts
OI	Chg OI	Volume	LTP	—	LTP	Volume	Chg OI	OI
39	+2	5	₹346.6	1,640	₹3.2	100	+40	53
3	0	0	₹342.0	1,680	₹4.1	177	-12	166
157	0	3	₹308.7	1,700	₹4.8	160	+23	135
30	0	0	₹290.0	1,720	₹5.8	13	+9	19
2	0	0	₹311.0	1,740	₹6.8	60	+22	49
61	+2	2	₹217.0	1,760	₹8.2	143	+9	142
4	+1	1	₹205.0	1,780	₹9.5	124	+14	47
467	-3	14	₹205.7	1,800	₹11.6	932	+12	748

Shaded cells are in the money against the underlying close. Green and red mark the move against the previous close — on the premium for LTP, on the position for change in OI. Settlement prices are the exchange's, not the last trade.

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	193	332	342	298	347	733	911	994	666	602	1,624
	-325	-289	-384	-253	-221	-941	-914	-996	-822	-682	-1,089
	105	-54	42	-45	-128	255	30	-27	250	39	-525
Net cash flow	-27	-10	1	0	-1	47	27	-29	93	-41	10
Free cash flow	193	332	342	298	347	44	34	4	-13	-39	554
CFO / Operating profit %	43.1%	80.3%	82.9%	83.6%	61.5%	47.3%	64.1%	62.4%	85.6%	57%	91.3%

Laurus Labs Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

3

Fund holders

Documents

Announcements

Events

Announcements

Announcements

3

Annual reports

Credit ratings

Investor Presentation and earnings call

18

1

1

29

Compounded sales growth

Compounded profit growth

Return on equity

Laurus Labs Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Futures3

Fund holders

Documents

Announcements

Events

Announcements

Ratio timeline

Announcements

Futures3

Annual reports

Credit ratings

Investor Presentation and earnings call

Dividends18

Board meetings1

Stock splits1

Option chain29

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

3

3

18

1

1

29